NewsBenzingaEntrada Therapeutics Q3 EPS $(0,94) supera la stima di $(1,01), ricavi a $905.000K inferiori alla stima di $5.871M Entrada Therapeutics Q3 EPS $(0,94) supera la stima di $(1,01), ricavi a $905.000K inferiori alla stima di $5.871M Benzinga 2026.11.05 13:02 (GMT+0) Open on Benzinga Other news APT Drops 24% in a Week, Erasing Its Autumn Rally Doubao Work: Daily Active Users Top 8 Million, Enterprise Client ARR Exceeds 2 Billion Yuan Rantizo (Nasdaq: RNTZ) Issues Letter to Shareholders Outlining Revenue-Focused American Drone Strategy After $258.8 Million Acquisition Dear Nvidia Stock Fans, Mark Your Calendars for December 10 Nvidia clarifies when it will — and won’t —keep financing neoclouds Global-E Online Stock Is Falling Wednesday: What's Going On?
Rantizo (Nasdaq: RNTZ) Issues Letter to Shareholders Outlining Revenue-Focused American Drone Strategy After $258.8 Million Acquisition